Micro-Sphere increases capsule filling capacity
The MG2 Tekna increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.
Switzerland-based CDMO Micro-Sphere has announced that its MG2 Tekna capsule filling machine is now online, adding further strength to its offering in encapsulation for inhalation products.
Situated in a dedicated cleanroom at Micro-Sphere’s recently expanded facility near Lugano in Ticino, the MG2 Tekna is in an area of controlled relative humidity of 20% (rH 20% +/- 5%), has a production capability of 110,000 cps/hour and increases the CDMO’s manufacturing capacity to up to 500 million capsules per year.
Alongside the MG2 Tekna machine the company has also invested in a MultiNETT, a net weight control system that monitors and reports the net weight of each dosed capsule. The MultiNETT system employs capacitive tomography to guarantee accuracy and precision and rejects all capsules it deems out of specification.
Michael Grassberger has recently been promoted to managing director at Micro-Sphere and is spearheading the company’s plans to increase its client portfolio with its greater capacity and improved services.
He said: “Micro-Sphere has always strived to offer the best possible service to our customers. This investment is the result of increasing client demand for encapsulation services and our drive to offer customers real commercial benefits.
“This new machinery will offer high-quality products, reduced production times, detailed batch reporting and, ultimately, cost savings.
“Added to our existing Harro Höfliger drum dosing equipment the new MG2 Tekna dosator system means we are the only CDMO in the world to offer these two important commercial size filling techniques under one roof.”
This latest announcement is the final step in Micro-Sphere’s 21 million CHF (€19 million) investment plan to expand its GMP manufacturing capabilities and comes as the company celebrates its 20th year in business.
Michael added: “In all of its 20 years our company has been committed to strengthening our niche capabilities in spray drying and inhalables. The expansion has seen a significant investment of time and resource and now enables us to move forward with our planned growth and hopefully garner success for at least another 20 years.”
Related News
-
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Pharma Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain. -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement. -
News BIOSECURE Act continues to loom over Chinese pharma manufacturers
With the US BIOSECURE Act on its way to passing into legislation, Chinese companies are facing declining revenues within the first half of 2024 as US pharmaceutical and healthcare companies pull their businesses from the country. -
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance